340B PATIENTS Act of 2025

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 4581 Introduced in House (IH)] <DOC> 119th CONGRESS 1st Session H. R. 4581 To ensure the accessibility of drugs furnished through the drug discount program under section 340B of the Public Health Service Act. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES July 22, 2025 Ms. Matsui (for herself, Mrs. Trahan, Mr. Tonko, Ms. Davids of Kansas, Ms. McCollum, Mr. Thanedar, Ms. Tlaib, Mr. Frost, and Ms. Castor of Florida) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To ensure the accessibility of drugs furnished through the drug discount program under section 340B of the Public Health Service Act. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SEC. 1. SHORT TITLE. This Act may be cited as the ``340B Pharmaceutical Access To Invest in Essential, Needed Treatments & Support Act of 2025'' or the ``340B PATIENTS Act of 2025''. SEC. 2. FINDINGS AND PURPOSES. (a) Findings.--Congress finds the following: (1) Section 340B of the Public Health Service Act (42 U.S.C. 256b) enables covered entities to stretch scarce resources as far as possible, reaching more patients and providing more comprehensive services than would be possible without such program. (2) Such section 340B requires drug manufacturers to offer discounted prices on covered outpatient drugs to covered entities participating in the program, and, as a condition of participating in the Medicaid program and part B of the Medicare program, drug manufacturers are required to offer drug discount pricing to covered entities when requested. (3) Savings on the purchase of drugs under the drug discount program under section 340B of the Public Health Service Act enables hospitals, clinics, and health ce